AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Genelux Corporation Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0044BNBY5
2.00▲ 0.02 (1.01%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.98
Day's Range
1.90 – 2.07
52-Week Range
1.90 – 8.54
Volume
648.7K
Avg Volume
300.3K
Share Statistics
Shares Outstanding
Employees
26
Exchange
XNAS
Listed
2023-01-26
Share count as of August 11, 2026

Genelux Corporation Common Stock (GNLX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Genelux Corporation Common Stock (GNLX)
What is Genelux Corporation Common Stock's Market Cap?
Genelux Corporation Common Stock's Market Cap is $90.5M, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's Price / Sales?
Genelux Corporation Common Stock's Price / Sales is 11311.3×, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's Revenue (TTM)?
Genelux Corporation Common Stock's Revenue (TTM) is $8.0K, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's Net Income (TTM)?
Genelux Corporation Common Stock's Net Income (TTM) is -$35.6M, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's EBITDA?
Genelux Corporation Common Stock's EBITDA is -$36.3M, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's Diluted EPS (TTM)?
Genelux Corporation Common Stock's Diluted EPS (TTM) is -0.79, based on as-reported figures from SEC (XBRL) filings.
What is Genelux Corporation Common Stock's EBITDA Margin?
Genelux Corporation Common Stock's EBITDA Margin is -453500.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GNLXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue————
YoY growth————
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
% of revenue————
Operating loss
% of revenue————
Other income:
Interest and Dividend Income (Non-Bank)
Bond accretion income
Total other income
Net loss
% of revenue————
Earnings Per Share (Basic)
Earnings Per Share (Diluted)